In the statement, NASS President Charles A. Mick, MD, applauds the transparency and calls for more data sharing and reanalysis to encourage ongoing critical thought.
“While this transparency is laudable, it is overdue,” wrote Dr. Mick. “Neither the original investigators nor industry were exonerated by this repeated data scrutiny, which led to conclusions quite disparate from those in their many published studies on their rhBMP-2 product. Open access post-market analysis may very well help identify mistaken conclusions and foster new creative analysis for existing data. But even the editors of Annals acknowledge that it is not feasible to apply these rigorous, costly and time-intensive methods of analysis to every clinical question.”
Medtronic underwrote the $2.5 million project after originally funneling millions of dollars to the original research. In the statement, NASS recommends post-publication efforts combined with efforts to improve the reporting of original research, including financial disclosure, authorship responsibilities and increased non-industry based funding.
More Articles on Spine:
Dr. Alvin Crawford Receives Lifetime Achievement Award
8 Emerging Business Issues in Spine Surgery
5 Ways Spine Cases Can Improve Profitability in Poorly Performing Surgery Centers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.